Abbott pumps over $450 million into new Ireland-based manufacturing site project and hiring spree – Endpoints News

As Ireland continues to see more investment and construction projects from pharmaceutical companies, another contender is looking to invest more in the Emerald Isle.

According to a report by Irish weather On Friday, Abbott Laboratories is investing 440 million euros, or about $451 million, to build a new manufacturing plant in Kilkenny, located in the southeast of the country, to manufacture more of its blood glucose monitors.

According to an Abbott spokesperson in an email to Terminal newsthe company expects over 800 people to be employed at the Kilkenny plant once it opens, with the rest employed at its Donegal site.

“Donegal is a key manufacturing site for Abbott’s diabetes care business, and we have invested heavily in expanding our operations there over the past four years. We are increasing our capital investments in Donegal, including facilities, production equipment and adding people to enable Donegal to better support our products globally,” the Abbott spokesperson said. .

For the new 250,000 square foot building in Kilkenny, the company will immediately begin recruitment for positions in engineering, quality control and medical device manufacturing, among others. The site, which the company hopes to have online by 2024, will be responsible for manufacturing its Freestyle Libre 3 continuous glucose monitoring system. And the company is optimistic that it can find the talent.

“The new Kilkenny site is attractive to our future employees as the region has strong educational links with South-East Technological University, allowing us to attract graduates from its Waterford and Carlow campuses,” the spokesperson said.

Abbot has had a strong presence in Ireland for over 75 years and currently employs over 5,000 people across nine locations. However, Abbott’s additional commitment comes at a time when several other big pharmaceutical companies are looking to conquer Irish soil for manufacturing.

Merck KGaA, Alexion, Eli Lilly and SK have all announced major new multi-million dollar sites or expansion projects across the country this year, and news from Abbott shows the speed of manufacturing development no don’t slow down.

Previous Fig Personal Loans Review 2022
Next Analysis: US decision to negotiate drug prices is a rare defeat for Big Pharma